CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Cash Flow Y/Y Annual
Kyverna Therapeutics Inc   (NASDAQ: KYTX)
Other Ticker:  
 
 

KYTX's Net Cash Flow Growth by Quarter and Year

Kyverna Therapeutics Inc 's Net Cash Flow results by quarter and year

 



KYTX Net Cash Flow (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - -8.05 0.00 0.00
3rd Quarter September - -26.97 0.00 0.00
2nd Quarter June - -92.67 0.00 0.00
1st Quarter March -39.75 189.65 0.00 0.00
FY   -39.75 61.96 0.00 0.00





KYTX Net Cash Flow first quarter 2025 Y/Y Growth Comment
Kyverna Therapeutics Inc in the first quarter 2025 recorded net cash outflow of $ -39.75 millions.

According to the results reported in the first quarter 2025, Kyverna Therapeutics Inc achieved the best Net Cash Flow growth in Biotechnology & Pharmaceuticals industry. While Kyverna Therapeutics Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the first quarter 2025.


KYTX Net Cash Flow ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Kyverna Therapeutics Inc 's first quarter 2025 Net Cash Flow $ -39.75 millions KYTX's Income Statement
Kyverna Therapeutics Inc 's first quarter 2024 Net Cash Flow $ 189.65 millions Quarterly KYTX's Income Statement


KYTX Net Cash Flow (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Go to KYTX Cash flow Statement >> Back to KYTX Growth rate Comparisons >>


Net Cash Flow first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Kyverna Therapeutics Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYTX's I. Quarter Q/Q Net Cash Flow Comment
Recent accomplishment of -39.75 millions by Kyverna Therapeutics Inc come out even more unfavourable compare to the -8.05 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Kyverna Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Kyverna Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KYTX's I. Quarter Q/Q Net Cash Flow Comment
I. Quarter 2025 net cash outflow of -39.75 millions by Kyverna Therapeutics Inc come out even more unfavourable compare to the net cash outflow -8.05 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Kyverna Therapeutics Inc achieved highest sequential Net Cash Flow growth. While Kyverna Therapeutics Inc 's Net Cash Flow growth quarter on quarter, overall rank is .


Kyverna Therapeutics Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Net Cash Flow 12 Months Ending $ -167.44 $ 61.96 $ 0.00 $ 0.00 $ 0.00
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #


Cumulative Net Cash Flow growth Comment
Kyverna Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -167 millions in the Mar 31 2025 period.
The situation is detiriorating as the cumulative net cash outflow is inflating from $ 61.96 millions for the period from Dec 31 2024 to Mar 31 2024 and $ millions for the twelve months ending in the quarter Mar 31 2024 mentioned.

Kyverna Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
Kyverna Therapeutics Inc ' has realized cumulative trailing twelve months net cash outflow of $ -167 millions in the Mar 31 2025 period.
The business is worsening as the cumulative net cash outflow is getting bigger from $ 61.96 millions in TTM ending quarter Dec 31 2024 and $ millions for the twelve months ending in the quarter a year ago mentioned.

Kyverna Therapeutics Inc achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
KYTX's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for KYTX's Competitors
Net Cash Flow Growth for Kyverna Therapeutics Inc 's Suppliers
Net Cash Flow Growth for KYTX's Customers

You may also want to know
KYTX's Annual Growth Rates KYTX's Profitability Ratios KYTX's Asset Turnover Ratio KYTX's Dividend Growth
KYTX's Roe KYTX's Valuation Ratios KYTX's Financial Strength Ratios KYTX's Dividend Payout Ratio
KYTX's Roa KYTX's Inventory Turnover Ratio KYTX's Growth Rates KYTX's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Mar 31 2025
Envista Holdings Corporation-3.53%$ -3.529 millions
Pluri Inc-6.84%$ -6.844 millions
Penumbra Inc-7.15%$ -7.151 millions
Regenxbio Inc -7.49%$ -7.489 millions
Sellas Life Sciences Group Inc -8.65%$ -8.650 millions
Viatris Inc -9.42%$ -9.417 millions
Fonar Corporation-10.96%$ -10.964 millions
Nautilus Biotechnology Inc -11.69%$ -11.687 millions
Zentalis Pharmaceuticals Inc -16.18%$ -16.183 millions
Arcus Biosciences Inc -27.59%$ -27.586 millions
Seastar Medical Holding Corporation-28.21%$ -28.206 millions
Contineum Therapeutics Inc -28.59%$ -28.591 millions
Staar Surgical Co-29.35%$ -29.354 millions
Ironwood Pharmaceuticals inc -32.21%$ -32.206 millions
Ani Pharmaceuticals Inc-33.90%$ -33.895 millions
Acurx Pharmaceuticals inc -35.22%$ -35.222 millions
Avenue Therapeutics Inc -35.65%$ -35.648 millions
Cryoport inc -37.53%$ -37.534 millions
Iqvia Holdings Inc -44.12%$ -44.118 millions
Amphastar Pharmaceuticals Inc -45.17%$ -45.168 millions
Seer Inc -46.61%$ -46.609 millions
Serina Therapeutics Inc -47.67%$ -47.669 millions
Humacyte Inc -48.91%$ -48.912 millions
Cytomx Therapeutics Inc -49.76%$ -49.758 millions
Rxsight Inc -50.80%$ -50.797 millions
Charles River Laboratories International inc -51.61%$ -51.609 millions
Blueprint Medicines Corporation-53.52%$ -53.519 millions
Royalty Pharma Plc-56.64%$ -56.640 millions
Skinvisible Inc -57.55%$ -57.553 millions
Adaptive Biotechnologies Corporation-59.03%$ -59.032 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com